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http:WHAT THIS PAPER ADDS
This study reports the early success of a novel catheter withdrawal protocol for carrying out radiofrequency
ablation using the Celon RFiTT device when compared with the manufacturer’s guidance for use. By reporting
our ﬁndings of improved ablation rates at early follow-up we hope other clinicians will adopt our technique,
which should help improve the success of RFiTT and patient outcomes when compared with other devices.Objective: Radiofrequency induced Thermal Therapy (RFiTT) is an established endovenous device for the
treatment of varicose veins. Our aim was to compare the manufacturer’s treatment guidance with a locally
developed treatment protocol on early truncal ablation rates between two patient cohorts.
Methods: The study was a retrospective analysis of prospectively collected data from 534 patients treated for
incompetent truncal saphenous veins between June 2009 and December 2012. Patients were treated either
according to the manufacturer’s guidance (Treatment 1), a single pullback rate of 1.5 s/cm, or according to local
protocol (Treatment 2), repeated vein treatment to visibly occlude the vein lumen. Follow-up at 6 weeks and 12
months included duplex examination, assessment of complications, and pain scores for the ﬁrst postoperative
week.
Results: 14 patients did not attend follow-up, leaving 98 patients (142 saphenous trunk treatments) who received
Treatment 1 and 422 patients (566 saphenous trunk treatments) who received Treatment 2. The two groups were
well matched for age, sex, and preoperative vein parameters. Six week occlusion rates were signiﬁcantly
different, with more treatment failures after Treatment 1 (Treatment 1 5.6% vs. Treatment 2 0.9%; p ¼ .0001).
Treatment 1 was more likely to produce incomplete ablation (3.5% vs. 0.9%) and non-ablation (2.1% vs. 0.0%)
compared with Treatment 2. No major complications occurred in either group and functional outcomes were
otherwise comparable between the two treatment methods. Longer-term follow-up at 12 months in the ﬁrst 100
patients undergoing Treatment 2 demonstrated maintenance of the early advantage, with partial recanalisations
in 9% and 2% for Treatments 1 and 2, respectively.
Conclusions: Six weeks after treatment with RFiTT, a protocol of repeated vein treatments to visibly obliterate
the vein lumen produced more reliable venous occlusion compared with manufacturer’s guidance. This
advantage is maintained at 12 months.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Endovenous thermal ablation techniques for varicose veins
provide superior clinical outcomes and patient satisfaction
when compared to surgery and foam sclerotherapy.1,2
Endovenous thermal ablations are minimally invasive
treatments that deploy an endoluminal catheter to deliver
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//dx.doi.org/10.1016/j.ejvs.2014.01.015vein occlusion. Laser energy and radiofrequency (RF) energy
are the two modalities most often used to generate
endothermal energy.
Bipolar RadioFrequency induced Thermal Therapy (RFiTT)
(Celon AG, Teltow, Germany) is one of three RF devices
currently in use. RFiTT uses alternating (bipolar) radio-
frequency current to cause high frequency oscillation of
molecules that generate heat (typically at 70e100 C)
directly in the vein wall during catheter pullback.3 This
heating is similar to the domestic microwave effect. RFiTT
treatment effects vein ablation through a combination of
intimal destruction, mural cell death, and coagulation of
collagen and other proteins.4,5 RFiTT may have certain ad-
vantages over other RF treatments.6 It has an in-built
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safety as follows: by dehydrating the vein wall the local
heating effect increases tissue resistance to RF conduction
to stop further current conduction, and overtreatment.
RFiTT is also promoted for needing little or no tumescent
anaesthesia and for having considerably faster application
times compared with other endovenous thermal
modalities.3,6
Prior to the recent publication of an industry sponsored
study and during the period of data collection for this study,
there were no deﬁnitive instructions for use (IFU) from the
manufacturer for the optimal method of treating patients
with the RFiTT technique.7 Their recommendation currently
and at the time was a catheter withdrawal at speeds of
1.5 s/cm and power settings of 18e20 W. Compared with
RF ablation using the VNUS Closurefast (Veneﬁt) catheter,
RFiTT has a ﬁner proﬁled 15 mm treatment tip (S1200-15
procurve catheter, Celon AG, Teltow, Germany) that allows a
greater range of applications including treatment of short
recurrent veins and incompetent perforators. Avoidance of
any need for standard laser protection precautions gives
RFiTT a major practical advantage over endovenous laser
ablation (EVLA) by allowing endovenous thermal ablation to
be undertaken in any treatment room setting.
The senior author, with prior experience of over 1000
endovenous treatments adopted RFiTT in 2009 using the
manufacturer’s recommendation (power 18 W, pullback
speed 1.5 s/cm). However, despite strict adherence to the
protocol, inconsistent truncal ablations were noted as fol-
lows: immediately following treatment the vein wall,
although oedematous, retained a patent and compressible
lumen (Fig. 1) and a few failed to ablate. This differed fromFigure 1. Duplex ultrasound image of GSV immediately following
single RFiTT treatment (Treatment 1). The vein wall is thickened/
oedematous (bold arrow) but retains a patent and compressible
echolucent lumen (thin arrow).his experience of laser-treated veins when there was total
absence of a visible lumen. An irritating aspect of RFiTT
treatment was the effect that coagulum formation at the
catheter tip, requiring removal, cleaning, and replacement,
had on accurate measurement of treatment speeds. The
difﬁculties encountered in trying to achieve the recom-
mended pullback prompted discussions with the manufac-
turer on the possibility of multiple treatments to the vein
segment. This led to a manufacturer approved change in the
local treatment protocol for RFiTT involving treatment and
re-treatment of target veins, irrespective of treatment time,
until the vein lumen became visibly obliterated on duplex
(Fig. 2), or until the catheter could no longer be passed.
The objective of this retrospective study of prospectively
collected data is to report early and short-term efﬁcacy
after RFiTT treatment of incompetent truncal saphenous
veins when using the manufacturer’s guidance (Treatment
1) and the new treatment protocol (Treatment 2).METHODS
Patients attending a single consultant’s varicose vein clinic
were studied. Patients underwent a single-stop varicose
veins assessment including venous duplex ultrasound ex-
amination performed by one of three vascular technologists
using a Toshiba Aplio 500 (Toshiba Medical Systems Ltd,
Crawley, UK) or a Philips CX50 (Philips Healthcare, Guildford,
UK) to determine the site(s) of saphenous reﬂux, and suit-
ability for endovenous thermal ablation. Patients with
incompetent saphenofemoral and/or saphenopopliteal
junctions (reﬂux >1 s) and an incompetent subfascial trunk
of 10 cm or more (great saphenous vein, GSV, small
saphenous vein, SSV, or anterior accessory saphenous vein,
AASV), or patients with residual incompetent saphenous
trunks despite previous veins surgery were offered RFiTT.
Pretreatment vein diameters were recorded in the standing
position at a distance of 10 cm distal to the saphenous
junction or, for recurrent veins, the proximal point of reﬂux.
Patients with deep vein thrombosis, superﬁcialFigure 2. Duplex ultrasound image of GSV immediately following
multiple pullback RFiTT treatment (Treatment 2). The vein is seen
to be echo-opaque and without a lumen (thin arrow) and the vein
wall cannot be distinguished.
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arterial insufﬁciency (ankle brachial index <0.85), severe
systemic diseases, cardiac pacemaker, or pregnant women
were not offered RFiTT treatment. Patients gave written
informed consent for treatment and all treatments were
undertaken as day cases using tumescent local anaesthesia.
All treatment and follow-up parameters were recorded onto
a prospectively maintained Excel database.RFiTT technique
Under duplex guidance, a 6F Terumo sheath (Radiofocus
Introducer II, Teruma UK Ltd, Egham, Surrey, UK) was
introduced into the target vein (usually at the distal point of
subfascial incompetence) using the Seldinger technique.
The ﬂexible RFiTT Celon procurve catheter was then posi-
tioned at the saphenous junction. Peri-venous tumescent
local anaesthesia (100e450 mL made up of 1L: 0.9%
saline þ 50 mg prilocaine þ 20 mL of 8.4% bicarbonate)
was administered to provide anaesthesia, compression, and
a heat-sink to the target vein. The procurve tip was repo-
sitioned ﬂush with the proximal (saphenous) junction after
completion of tumescence and connected to the Celon Lab-
precision generator (Celon AG, Teltow, Germany) with po-
wer set to 18 W. The foot switch was then activated and
treatment performed.
Catheter pullback rate was monitored through the
RFiTT’s in-built acoustic impedance feedback mechanism.
When feedback signalled accumulation of coagulum on the
applicator tip, the procurve was removed, cleaned, and re-
inserted to continue treatment as follows:Treatment 1: single slow catheter pullback with the
aim of achieving a withdrawal of 1.5 s/cm. Usually
achieved in a single passage, occasionally the catheter
would need to be removed for cleaning, in which case
the point reached was carefully marked. The
treatment was then continued from that point with
only a few centimetres overlap.
Treatment 2: multiple retreatments until luminal
obliteration (visible echogenic centre on duplex) or
until the catheter could no longer be passed,
irrespective of treatment time. Catheter withdrawal
and retreatment was progressed in 5e10 centimetre
distances and each segment was treated until luminal
ablation before progressing onto the next 5e10
centimetre segment. Generous overlaps of segments
was employed. The smooth tip of the procurve
catheter allowed this to be achieved without vein wall
perforation.All incompetent trunks in target limbs were treated at the
same sitting. It is our policy to perform phlebectomies at
the time of thermal ablation. Only a few C5/6 limbs did not
receive phlebectomies. Coban bandaging was applied for 48
hours after phlebectomy and all limbs had compression
stockings applied for 2 weeks. Patients were mobilised
immediately after treatment and were allowed to return tonormal activity as soon as able. Low molecular weight
heparin was given selectively as dictated by hospital policy
on prophylactic anticoagulation. No analgesics were pre-
scribed; however, patients were advised to take their usual
oral pain killers if required.
Groups were compared using treatment time (s/cm, a
reﬂection of energy delivered), rather than approximations
such as the endovenous energy ﬂuence equivalent, because
of the unique way in which RFiTT energy is delivered.
Follow-up
All patients who had undergone Treatment 1 and the ﬁrst
100 who had undergone Treatment 2 were offered follow-
up at 6 weeks and 12 months. We were not funded for
12-month follow-up for the remaining patients who had
undergone Treatment 2. Treated limbs were assessed clini-
cally and treated trunks were examined by duplex ultra-
sound. The ‘worse pain’ score during the ﬁrst week was
obtained on an 11 point visual analogue score (0 ¼ no pain,
10 ¼ worst pain imaginable). Non-compressibility and
absence of colour ﬂow signals on duplex throughout the
treated length of vein was chosen as the primary outcome
of success for this comparison. Treatment failure was
deﬁned as any treated vein demonstrating compressibility
and ﬂow/reﬂux irrespective of clinical improvement. Two
different failure types were deﬁned as follows:
 Partial ablation: compressibility and ﬂow/reﬂux
anywhere in the treated vein >2 cm from the
saphenous junction, but preoperative truncal reﬂux
abolished.
 Failed ablation: compressibility and ﬂow/reﬂux
throughout the treated vein trunk irrespective of vein
diameter.Statistics
For comparison of the two groups, categorical variables
were compared using the chi-square test and the two-tailed
Fishers exact test; continuous variables were compared with
the unpaired t-test. A p value of <.05 was considered sta-
tistically signiﬁcant. All statistical analyses were performed
with SPSS statistical software (SPSS, Inc., Chicago, IL, USA).
RESULTS
Database interrogation revealed that between June 2009
and December 2012 534 patients had varicose vein treat-
ment with RFiTT as follows: 101 patients had Treatment 1 to
April 2010, after which 433 patients had Treatment 2. Three
and 11 patients in the groups, respectively, failed to attend
their 6-week follow-up appointment and are not considered
further. This gave follow-up rates of 97.0% and 97.5%,
respectively, at 6 weeks. The groups were well matched for
demographic and clinical characteristics, with no difference
being demonstrated for age, sex, sidedness, primary or
recurrent status, or whether the veins were unilateral or
bilateral (Table 1). There was a statistical difference in the
Table 1. Patients’ demographics and clinical characteristics.
Treatment 1 Treatment 2 p
Number patients 98 422
Median age (SD) 53.9 (14.4) 54.4 (14.1) .757
Sex .305
Male, n (%) 44 (45) 165 (39)
Female, n (%) 54 (55) 257 (61)
Primary n (%) 88 (90) 386 (92) .425
Recurrent n (%) 10 (10) 34 (8)
Side .319
Limbs treated 124 530
Right, n (%) 62 (50) 291 (54.9)
Left, n (%) 62 (50) 239 (45.1)
CEAP classiﬁcation (limbs) 124 530 .0001
C2, n (%) 69 (55.6) 406 (76.6)
C3, n (%) 16 (12.9) 20 (3.8)
C4, n (%) 31 (24.6) 68 (12.8)
C5, n (%) 6 (4.2) 30 (5.7)
C6, n (%) 2 (1.4) 6 (1.1)
Unilateral 72 (74) 312 (74) 1.000
Bilateral 26 (26) 109 (26)
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Treatment 1 having a higher proportion of C3-6 limbs
(p ¼ .0001).
For Treatment 1, 98 patients received 142 saphenous
trunk treatments (109 GSV, 24 SSV, and 9 AASV) and for
Treatment 2, 422 patients received 566 trunk treatments
(441 GSV, 94 SSV, and 31 AASV). There were no signiﬁcant
differences in diameters or treated lengths in the two
groups for GSV, SSV, or AASV (Table 2). Treatment 2 took
approximately 2.5 times longer to deliver (s/cm) compared
with Treatment 1 for all three vein trunks. For GSV, Treat-
ment 1 took 1.8  0.42 s/cm, whereas Treatment 2 took
5.0  1.2 s/cm (p < .0001). For SSV, Treatment 1 took
1.9  0.5 s/cm, whereas treatment 2 took 4.8  1.6 s/cm
(p < .0001), and for AASV, Treatment 1 took 1.7  0.6 s/cm,
whereas Treatment 2 took 4.4  1.7 s/cm (p < .0001).Table 2. Distribution of treated trunks between the two treatment
groups.
Treatment 1 Treatment 2 p
Saphenous trunks treated 142 566 .695
GSV, n (%) 109 (76.8) 441 (77.9)
SSV, n (%) 24 (16.9) 94 (16.6)
AASV, n (%) 9 (6.3) 31 (5.5)
Mean GSV diameter, mm (SD) 7.10 (1.04) 7.21(1.83) .593
Mean SSV diameter, mm (SD) 6.37 (1.21) 6.55 (1.59) .667
Mean AASV diameter, mm (SD) 6.0 (1.32) 6.21(1.48) .728
Mean GSV length, cm (SD) 37.59 (13.91) 36.42 (7.07) .315
Mean SSV length, cm (SD) 25.29 (7.75) 22.65 (5.36) .091
Mean AASV length, cm (SD) 18.89 (7.03) 18.88 (7.98) .998
GSV ¼ great saphenous vein; SSV ¼ small saphenous vein;
AASV ¼ anterior saphenous vein.Early outcomes (6 weeks post-procedure)
At 6 week follow-up, overall complete occlusion rates were
signiﬁcantly worse for Treatment 1 (134/142; 94.4%) than
for Treatment 2 (561/566; 99.1%) (p ¼ .0011). Partial
ablation occurred in 5/142 trunks (3.5%) after Treatment 1
and 5/561 trunks (0.9%) after Treatment 2. Non-ablation
was found in 3/142 (2.1%) and 0/566 (0%) for the two
groups, respectively. These differences were attributable to
the GSV treatment which achieved a partial ablation in ﬁve
patients from Treatment group 1 and four patients from
Treatment group 2 (p ¼ .016) and non-ablation in three
patients from Treatment group 1 and 0 patients from
Treatment group 2 (p ¼ .0068). However, there was no
difference in outcome after Treatment 1 and Treatment 2
for SSV and AASV (p ¼ 1.000 for all combinations).
There were no major side effects such as infection, deep
vein thrombosis/pulmonary embolism, skin pigmentation,
or burns in either group. Some patients reported minordiscomfort during the ﬁrst week in both groups; however,
there were no differences in patient reported pain scores
(mean visual analogue scores (0e10): 1.24 and 1.13 after
Treatment 1 and Treatment 2, respectively (p ¼ .401)).
Phlebitis was reported in three limbs in each treatment
group (2.4% and 0.6% for Treatment 1 and Treatment 2,
respectively). This did not reach statistical signiﬁcance. For
limbs that had SSV ablation, transient sural nerve paraes-
thesia was seen in no limbs after Treatment 1 but two
(2.2%) limbs after Treatment 2, again this was not signiﬁ-
cant. We could not determine whether the sural nerve
paraesthesia was caused by RFiTT treatment or stab
phlebectomies.
Short-term outcomes (12-months post procedure)
All patients in Treatment group 1 and the ﬁrst 100 patients
in Treatment group 2 were offered follow-up at 12 months.
In this subgroup of 100 patients from Treatment group 2,
demographic and clinical characteristics were not different
from Treatment group 1, except the proportion of C3-C6
limbs which was also lower than in patients of Treatment
group 1 (data not shown). There were also no differences in
diameters or treated lengths of any saphenous trunks be-
tween the two groups.
From Treatment group 1, 84/98 patients (excluding the
three patients whose trunks were not ablated at 6 weeks)
were successfully followed-up, and 96/100 patients from
Treatment group 2. No patients from either group reported
symptoms or signs of ongoing chronic venous insufﬁciency
or recurrent varicose veins. However, in this report from an
NHS clinical practice, our objective was to assess efﬁcacy of
vein ablation from changing from Treatment 1 to Treatment
2. No objective assessment of disease severity, such as
Venous Clinical Severity Scoring, nor disease speciﬁc quality
of life questionnaires, such as the Aberdeen Varicose Veins
Questionnaires, were performed. There was some objective
documentation of visible varicosities (unrelated to the ab-
lated trunks) at the time of duplex imaging in both groups.
Duplex ultrasound results were as follows: in treatment
group 1, 8/93 (9%) GSVs scanned had partial recanalisation
compared with 2/106 (2%) GSVs in Treatment group 2
(p ¼ .05). There were no full recanalisations in either group.
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SSVs from Treatment group 2 had partial recanalisation. No
SSVs from either group had full recanalisation. Nine AASVs
from each group were fully ablated with no partial or full
recanalisations observed.DISCUSSION
Endovenous thermal ablation is not a new concept. Watts
ﬁrst used the technique in 1972 when he used a specially
designed electrode to destroy the GSV.8 He identiﬁed a
withdrawal rate of 2.5 s/cm as optimal, with higher energy
inputs causing local nerve irritation. He observed the pro-
cedure to be “much less distressing” than surgery and it
could be done on an outpatient basis. Watts’ work, how-
ever, went unrecognised and it took almost three decades
before the rediscovery of endovenous thermal ablation. In
recent years endovenous thermal ablation has superseded
other modalities wherever it has been introduced. It is at
least as efﬁcacious as open varicose veins surgery, and its
advantages of minimal invasiveness, performance under
tumescent anaesthesia and elimination of the need for a
hospitalisation makes for attractive healthcare economics.
Indeed recently published NICE guidelines advocate that
patients with symptomatic VVs and truncal reﬂux should be
offered initially endovenous thermal ablation over open
surgery or foam sclerotherapy.9 Radiofrequency (RF) ther-
mal ablation by VNUS Closurefast (Veneﬁt), RFiTT and now
EndoVenousRadioFrequncy (EVRF) has gained support in
terms of better patient reported outcomes when compared
with laser. Reported advantages of RF include reduced
bruising, haematoma, pain, induration, and phlebitis.1012
RFiTT is promoted for having further clinical beneﬁts.6
The catheter tip is easily visualised on duplex to enhance
accurate placement at the saphenous junction and contin-
uous impedance monitoring providing acoustic feedback
guides energy delivery to the vein wall and warns when the
treatment tip is outside the vein. This virtually eliminates
any potential for skin burns. Also there is automatic power
cut-off when the catheter tip enters the sheath, which
cannot therefore be heated.
The mechanism of RFiTT generates heat directly in the vein
wall rather than heating the vein through direct contact or the
generation of steambubbles via conduction and convection as
described for laser.13 This thermal effect of RFITT localises to
the vein tissue between two treatment electrodes. Temper-
atures reach approximately 70e100 C to cause irreversible
denaturation of collagen, elastin, and cellular proteins that
shrink to occlude the vessel wall.4,5 As a result there is less
direct physical wall damage and perforation. This has been
proposed as a likely reason for the signiﬁcantly reduced pain
reported after RFiTT.6,14 Although this histological mechanism
of action has been demonstrated ex vivo, clinical treatment
failures in vivo, up to 26% in one recent study, suggest that the
proposed histological changes may not always be achieved in
clinical practice.15
This report of a single surgeon’s experience has limita-
tions and strengths. As a report generated from routineclinical practice, this study was not prospectively designed.
The groups were not randomised, and data collection was
performed by the clinical team (surgeon, nurse consultant,
and vascular scientist). Nevertheless, this was a “real life”
study and patients’ clinical and demographic factors were
well matched in the two groups except for CEAP classiﬁ-
cation. The greater proportion of C3-C4 legs in Treatment
group 1 compared with Treatment group 2 may have been
more difﬁcult to ablate because of the increased ﬁbrosis in
these trunks related to chronic venous inﬂammatory pro-
cess. However, we would argue that a method with
repeated treatments would be better for managing the
more ﬁbrotic and resistant veins. Other factors likely to be
signiﬁcant in this regard such as vein length and vein
diameter were well matched between the two groups. The
6e8 week follow-up time, the normal time for planned
outpatient review, was used to assess early efﬁcacy of
ablation in this report. Longer-term follow-up at 12 months
demonstrated maintenance of the early advantage of
Treatment 2. Our local commissioners withdrew funding for
further 12 month follow-up after the improved results of
the ﬁrst 100 Treatment 2 patients were presented to them.
The RFITT occlusion rates of 94.4% and 99.1% compare
favourably with outcomes published by Goode (74% at 237
days), Boon (88.7% at 1 year), and Braithwaite (92.4% at
180 days).7,1416 Signiﬁcant difference in occlusion rates in
treatment groups was demonstrated only for GSV treat-
ment. Treatment time (a surrogate marker for energy
applied at constant power) was the only difference in the
treatment groups, with approximately 2.5 times more en-
ergy being delivered in Treatment 2 than in Treatment 1.
Any explanation as to why this difference should have been
seen only in the GSV rather than the other saphenous
trunks probably lies in differences in vein diameter (mean
GSV diameter 11% greater than SSV and AASV diameter)
and vein wall thickness (not studied in this report). Because
RFiTT generates heat in the tissue volume between two
electrodes at the catheter tip, tissue injury for a given
amount of energy delivered is likely to be related to these
vein wall properties that tend to be greater for GSV. Simi-
larly, inherently smaller vein trunk diameters may explain
the lack of difference in treatment efﬁcacy for the smaller/
thinner walled AASV and SSV, where both treatments
strategies were equally effective.
The greater energy delivered with Treatment 2 did not in-
crease patient-reported pain scores. This suggests that the
increased energy delivered to the vein wall with Treatment 2
did not cause more damage to surrounding tissue or vein wall
perforations. In fact, side effect proﬁles of the two approaches
were similar with phlebitis, the most common complication,
occurring in 2.4% and 0.6% after Treatments 1 and 2,
respectively. Treatment 2 did show a non-signiﬁcance trend
towards sural nerve paraesthesia after SSV RFiTT.Tessman has
previously reported this in 12.5% of 24 patients who under-
went SSV ablation with RFiTT.14 This might be a possible
limitation of RFiTT. The proposed mechanism of injury is that
RF energy generates heat remotely in nerve tissue through
molecular oscillations to produce paraesthesia. This
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methods that have a more direct energy transmission inside
the vein, with less likelihood of remote injury.14 Another
possible explanation is that these are chance events caused by
the variable anatomical relationship of the sural nerve to the
SSV. When the sural nerve lies directly on the SSV, thermal
injury would be unavoidable irrespective of the thermal
ablation method used. Whatever its mechanism, sural nerve
paraesthesia is rare (1.76% SSV RFiTTs in this study), requires
further investigation but should not limit the use of RFiTT in
SSV treatment. Its possibility should form part of the consent
process. Further confounding the issue is that phlebectomy (a
well-recognised cause of neural injury) was undertaken in our
patients who developed sural nerve paraesthesia.
It has been suggested that RFITT, through its feedback
mechanism, inherently applies more energy to vein seg-
ments in which more energy is required (i.e. more energy
for thicker vein walls and less energy for thinner vein
walls).7,14 This is not supported by the present study where
the thicker walled GSV was better ablated only with
increased energy delivery through repeated treatment.
Also, the RFiTT-induced tissue dehydration that provides the
treatment’s impedance feedback (and supposedly assures
treatment at any given point) must be a transient event
because treated vein segments could be successfully
retreated almost immediately in Treatment 2.
CONCLUSIONS
Despite its attractions, previous authors have recognised
the relatively inferior ablation rates of RFiTT. This study adds
to the evidence by demonstrating that, in addition to
reducing the power setting from 25 W to 18 W or less
(suggested as one method of improving RFiTT efﬁcacy),
application of greater tissue energy (by repeated treat-
ments) improves GSV ablation and may enhance long-term
outcomes after RFiTT in all saphenous trunks. This should go
some way to answering the call made by authors such as
Goode and Tessman that occlusion rates after RFITT must
be improved.14,15
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